Metformin, a first-line therapy for T2DM, improves insulin sensitivity and has demonstrated potential anti-tumor activity in experimental models by inhibiting the mammalian target of rapamycin (mTOR) signaling pathway10–14. This evidence concerns the gene MTOR and neoplasm.